Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1995 1
1996 2
1997 34
1998 55
1999 60
2000 58
2001 93
2002 93
2003 83
2004 93
2005 84
2006 97
2007 74
2008 76
2009 61
2010 83
2011 79
2012 64
2013 52
2014 59
2015 69
2016 54
2017 51
2018 42
2019 42
2020 33
2021 29
2022 15
2023 22
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

1,508 results

Results by year

Filters applied: . Clear all
Page 1
Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A, Pommier Y. Thomas A, et al. Clin Cancer Res. 2019 Nov 15;25(22):6581-6589. doi: 10.1158/1078-0432.CCR-19-1089. Epub 2019 Jun 21. Clin Cancer Res. 2019. PMID: 31227499 Free PMC article. Review.
Clinical status and optimal use of topotecan.
Takimoto CH, Arbuck SG. Takimoto CH, et al. Oncology (Williston Park). 1997 Nov;11(11):1635-46; discussion 1649-51, 1655-7. Oncology (Williston Park). 1997. PMID: 9394364 Free article. Review.
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study.
Blackhall F, Jao K, Greillier L, Cho BC, Penkov K, Reguart N, Majem M, Nackaerts K, Syrigos K, Hansen K, Schuette W, Cetnar J, Cappuzzo F, Okamoto I, Erman M, Langer SW, Kato T, Groen H, Sun Z, Luo Y, Tanwani P, Caffrey L, Komarnitsky P, Reinmuth N. Blackhall F, et al. J Thorac Oncol. 2021 Sep;16(9):1547-1558. doi: 10.1016/j.jtho.2021.02.009. Epub 2021 Feb 16. J Thorac Oncol. 2021. PMID: 33607312 Free article. Clinical Trial.
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohé C, Farago AF, López-Vilariño JA, Cullell-Young M, Nieto A, Vasco N, Gómez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sánchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Dómine M, Paz-Ares L. Aix SP, et al. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14. Lancet Respir Med. 2023. PMID: 36252599 Clinical Trial.
Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.
Takahashi N, Hao Z, Villaruz LC, Zhang J, Ruiz J, Petty WJ, Mamdani H, Riess JW, Nieva J, Pachecho JM, Fuld AD, Shum E, Chauhan A, Nichols S, Shimellis H, McGlone J, Sciuto L, Pinkiert D, Graham C, Shelat M, Kattappuram R, Abel M, Schroeder B, Upadhyay D, Krishnamurthy M, Sharma AK, Kumar R, Malin J, Schultz CW, Goyal S, Redon CE, Pommier Y, Aladjem MI, Gore SD, Steinberg SM, Vilimas R, Desai P, Thomas A. Takahashi N, et al. JAMA Oncol. 2023 Dec 1;9(12):1669-1677. doi: 10.1001/jamaoncol.2023.4025. JAMA Oncol. 2023. PMID: 37824137 Clinical Trial.
Topotecan-induced bronchiolitis.
Edgerton CC, Gilman M, Roth BJ. Edgerton CC, et al. South Med J. 2004 Jul;97(7):699-701. doi: 10.1097/00007611-200407000-00018. South Med J. 2004. PMID: 15301130
1,508 results